Jason N Barreto1, Kristen T Peterson2, Erin F Barreto3, Kristin C Mara4, Ross A Dierkhising4, Nelson Leung5, Thomas E Witzig6, Carrie A Thompson6. 1. Department of Pharmacy, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Barreto.Jason@mayo.edu. 2. Department of Pharmacy, Duke University Medical Center, 2301 Erwin Road, Durham, NC, 27710, USA. 3. Department of Pharmacy, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 4. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 5. Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 6. Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Abstract
BACKGROUND: In patients exposed to high-dose methotrexate (HDMTX; >1g/m2) with a history of elevated methotrexate (MTX) concentrations during previous doses, it is unclear whether prescribing high-dose leucovorin (HDLV) rescue limits future high levels or reduces the likelihood of acute kidney injury (AKI). METHODS: This retrospective, single-center study longitudinally followed adult lymphoma patients treated with HDMTX between 1/1/2011 and 10/31/2017 from diagnosis until 30 days after the last HDMTX dose. Endpoints included elevated MTX concentrations at 48 h (>1.0 μmol/L) and incident AKI after each HDMTX dose. RESULTS: The 321 included patients had a median (IQR) age of 65 (57, 72) years, 190 (59%) were male, and 293 (91%) were Caucasian. There were 1558 HDMTX doses [median (IQR) 3 (2, 6) doses per patient] prescribed with 265 (83%) patients receiving more than one MTX dose. Those receiving HDLV rescue were more likely to have an elevated MTX concentration after that dose (OR = 2.69, 95% CI: 1.75-4.11, p < 0.001). Receiving HDLV rescue was associated with a greater likelihood of AKI after MTX (OR = 2.18, 95% CI: 1.38-3.43, p < 0.001). Hospital LOS was longer in those prescribed empiric HDLV rescue after MTX than those prescribed standard leucovorin with an estimated difference of 1.1 days, (95% CI: 0.5-1.7, p < 0.001). CONCLUSION: Sequential HDMTX doses are associated with a significant incidence of elevated MTX levels and AKI during lymphoma management. HDLV rescue prescribed during subsequent MTX doses in patients with a previously elevated level was not associated with improved safety outcomes. The optimal supportive care strategy following HDMTX administration requires further investigation.
BACKGROUND: In patients exposed to high-dose methotrexate (HDMTX; >1g/m2) with a history of elevated methotrexate (MTX) concentrations during previous doses, it is unclear whether prescribing high-dose leucovorin (HDLV) rescue limits future high levels or reduces the likelihood of acute kidney injury (AKI). METHODS: This retrospective, single-center study longitudinally followed adult lymphomapatients treated with HDMTX between 1/1/2011 and 10/31/2017 from diagnosis until 30 days after the last HDMTX dose. Endpoints included elevated MTX concentrations at 48 h (>1.0 μmol/L) and incident AKI after each HDMTX dose. RESULTS: The 321 included patients had a median (IQR) age of 65 (57, 72) years, 190 (59%) were male, and 293 (91%) were Caucasian. There were 1558 HDMTX doses [median (IQR) 3 (2, 6) doses per patient] prescribed with 265 (83%) patients receiving more than one MTX dose. Those receiving HDLV rescue were more likely to have an elevated MTX concentration after that dose (OR = 2.69, 95% CI: 1.75-4.11, p < 0.001). Receiving HDLV rescue was associated with a greater likelihood of AKI after MTX (OR = 2.18, 95% CI: 1.38-3.43, p < 0.001). Hospital LOS was longer in those prescribed empiric HDLV rescue after MTX than those prescribed standard leucovorin with an estimated difference of 1.1 days, (95% CI: 0.5-1.7, p < 0.001). CONCLUSION: Sequential HDMTX doses are associated with a significant incidence of elevated MTX levels and AKI during lymphoma management. HDLV rescue prescribed during subsequent MTX doses in patients with a previously elevated level was not associated with improved safety outcomes. The optimal supportive care strategy following HDMTX administration requires further investigation.
Authors: M J Glantz; B F Cole; L Recht; W Akerley; P Mills; S Saris; F Hochberg; P Calabresi; M J Egorin Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Laila Holmboe; Anders M Andersen; Lars Mørkrid; Lars Slørdal; Kirsten Sundby Hall Journal: Br J Clin Pharmacol Date: 2012-01 Impact factor: 4.335
Authors: Jeremy S Abramson; Matthew Hellmann; Jeffrey A Barnes; Peter Hammerman; Christiana Toomey; Tak Takvorian; Alona Muzikansky; Ephraim P Hochberg Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Berna Demiralp; Lane Koenig; Jaya Kala; Chaoling Feng; Elizabeth G Hamlett; Marie Steele-Adjognon; Suzanne Ward Journal: Clinicoecon Outcomes Res Date: 2019-02-07
Authors: Jason N Barreto; Kianoush B Kashani; Kristin C Mara; Andrew D Rule; John C Lieske; Callen D Giesen; Carrie A Thompson; Nelson Leung; Thomas E Witzig; Erin F Barreto Journal: Kidney Int Rep Date: 2022-03-26
Authors: Jason N Barreto; Joel M Reid; Carrie A Thompson; Kristin C Mara; Andrew D Rule; Kianoush B Kashani; Nelson Leung; Thomas R Larson; Renee M McGovern; Thomas E Witzig; Erin F Barreto Journal: Clin Transl Sci Date: 2021-08-23 Impact factor: 4.689